Kamada (KMDA) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kamada (KMDA) has outperformed Neurogene (NGNE) over the past year, gaining 14.7% versus a gain of 10.4%. Over five years, KMDA leads with a +22.7% price change compared with -78.3% for NGNE. Neurogene is the larger company by market cap ($458.5 million vs $446.8 million), about 1.0 times the size, while Kamada is growing revenue faster (+12.1% vs -100.0%).
Kamada pays a dividend yielding 7.24%, while Neurogene does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KMDA | NGNE |
|---|---|---|
| Share price | $7.74 | $22.15 |
| Market cap | $446.85M | $458.53M |
| 1-day change | -1.15% | -3.40% |
| YTD return | +9.63% | +7.52% |
| 1-year return | +14.67% | +10.42% |
| 5-year return | +22.66% | -78.33% |
| P/E ratio (TTM) | 20.37 | — |
| Forward P/E | 13.34 | — |
| EPS (TTM) | $0.38 | $-5.03 |
| Dividend yield | 7.24% | 0.00% |
| Annual dividend | $0.56 | $0.00 |
| Revenue (latest FY) | $180.46M | $0 |
| Revenue growth (YoY) | +12.12% | -100.00% |
| Net income (latest FY) | $20.20M | $-90.35M |
| Gross margin | 42.34% | — |
| Operating margin | 14.54% | — |
| Net margin | 11.19% | — |
| 52-week high | $9.35 | $43.66 |
| 52-week low | $6.63 | $15.93 |
| Distance from 52-week high | -17.22% | -49.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.65% | +250.47% |
| Average volume | 121.87K | 307.78K |
| Shares outstanding | 57.73M | 20.70M |
| Employees | 462 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
- Kamada grew revenue faster in its latest fiscal year (+12.12% vs -100.00%).
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
KMDA vs NGNE FAQ
Which is bigger, Kamada or Neurogene?
Neurogene (NGNE) is larger, with a market capitalization of $458.53M compared with $446.85M for Kamada (KMDA).
Which stock has performed better over the past year, KMDA or NGNE?
KMDA returned +14.67% over the past 12 months, compared with +10.42% for NGNE (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Kamada or Neurogene?
Kamada pays a dividend yielding 7.24%, while Neurogene does not currently pay a regular dividend.
Are Kamada and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.